Nous nous concentrons continuellement sur la recherche et l’innovation. Découvrez nos dernières découvertes et perspectives ci-dessous.
ENDRA presents AASLD Symposium with Dr Malik and Dr Kowdley on non invasive diagnostic of NAFLD and the current and future therapies in NASH
VISIONNER LA VIDÉO >
ENDRA presents AASLD Symposium with Dr Malik and Dr Kowdley on non invasive diagnostic of NAFLD and the current and future therapies in NASH
2020 Presentation by Raza Malik, M.D., Ph.D.
VISIONNER LA VIDÉO >
2020 Presentation by Raza Malik, M.D., Ph.D.
Presentation by Raza Malik, M.D., Ph.D.
Francois Michelon, CEO of ENDRA Life Sciences Inc., explains how ENDRA is leading early detection of liver diseases and issues with existing tools’ diagnostic and accessibility properties.
VISIONNER LA VIDÉO >
Francois Michelon, CEO of ENDRA Life Sciences Inc., explains how ENDRA is leading early detection of liver diseases and issues with existing tools’ diagnostic and accessibility properties.
Francois Michelon, CEO of ENDRA Life Sciences Inc., discusses childhood obesity and the risks of NAFLD.
VISIONNER LA VIDÉO >
Francois Michelon, CEO of ENDRA Life Sciences Inc., discusses childhood obesity and the risks of NAFLD.
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ technology can help detect and monitor NAFLD-NASH caused by hepatitis.
VISIONNER LA VIDÉO >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ technology can help detect and monitor NAFLD-NASH caused by hepatitis.
Renaud Maloberti, CCO of ENDRA Life Sciences Inc., talks about the importance of early diagnosis and access to healthcare.
VISIONNER LA VIDÉO >
Renaud Maloberti, CCO of ENDRA Life Sciences Inc., talks about the importance of early diagnosis and access to healthcare.
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ is focused on early detection of liver disease by measuring liver fat.
VISIONNER LA VIDÉO >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ is focused on early detection of liver disease by measuring liver fat.
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about the significance of CE Mark certification.
VISIONNER LA VIDÉO >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about the significance of CE Mark certification.
ENDRA Life Sciences participe activement aux collaborations de recherche externes avec des organismes de recherche universitaires et privés. La politique de ENDRA Life Sciences vise à limiter à 15 % le montant des coûts indirects associés à tout financement qu’elle fournit à tout organisme de recherche, par le biais d’accords de parrainage de recherche, d’accords de recherche collaborative ou d’autres accords liés à la recherche.
ENDRA ne prendra pas en charge les frais généraux, coûts indirects ou autres coûts associés à la recherche qui dépasse quinze pour cent (15 %) du montant de recherche stipulé dans le contrat.
|
ENDRA is certified to ISO 13485:2016 Learn More> |
ENDRA operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
Certificate number: MD 697226
Effective Date: 2022-04-02
Expiry Date: 2025-04-01
